These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 35020496)

  • 1. Association of
    Toda-Oti KS; Stefano JT; Cavaleiro AM; Carrilho FJ; Correa-Gianella ML; Oliveira CPMS
    Metab Syndr Relat Disord; 2022 Mar; 20(2):114-123. PubMed ID: 35020496
    [No Abstract]   [Full Text] [Related]  

  • 2. Association between the CYBA and NOX4 genes of NADPH oxidase and its relationship with metabolic syndrome in non-alcoholic fatty liver disease in Brazilian population.
    Rabelo F; Stefano JT; Cavaleiro AM; Lima RVC; de Campos Mazo DF; Carrilho FJ; Correa-Giannella ML; Oliveira CP
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):330-335. PubMed ID: 30087027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between UCP3 gene polymorphisms and nonalcoholic fatty liver disease in Chinese children.
    Xu YP; Liang L; Wang CL; Fu JF; Liu PN; Lv LQ; Zhu YM
    World J Gastroenterol; 2013 Sep; 19(35):5897-903. PubMed ID: 24124336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis.
    DeBoer MD; Lin B; Filipp SL; Cusi K; Gurka MJ
    Nutr Res; 2021 Apr; 88():34-43. PubMed ID: 33743323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China.
    Yang RX; Zou ZS; Zhong BH; Deng H; He FP; Shi JP; Zhao CY; Mi YQ; Zhou YJ; Di FS; Zheng RD; Du Q; Shang J; Popovic B; Chen J; Fan JG
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):426-432. PubMed ID: 34246549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 9.
    Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
    World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.
    Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H
    Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
    Türker F; Oral A; Şahin T; Türker BÇ; Koçak E; Ataoğlu HE; Ahbab S
    J Int Med Res; 2021 Nov; 49(11):3000605211056841. PubMed ID: 34763561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.
    Patton HM; Yates K; Unalp-Arida A; Behling CA; Huang TT; Rosenthal P; Sanyal AJ; Schwimmer JB; Lavine JE
    Am J Gastroenterol; 2010 Sep; 105(9):2093-102. PubMed ID: 20372110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.
    Duseja A; Singh SP; Mehta M; Shalimar ; Venkataraman J; Mehta V; Devadas K; Kar SK; Goyal O; Nagral A; Saigal S; Nijhawan S; Praharaj D; Shukla A; Sharma B; Narayanasamy K; Kumar P; Rao PN; Arora A; Mehta R; Asati P; Ranjan P; Koshy A; Alam S; Mukewar S; Mukewar S; Mohan Prasad VG; Rastogi M; Sanyal AJ
    Metab Syndr Relat Disord; 2022 Apr; 20(3):166-173. PubMed ID: 35085026
    [No Abstract]   [Full Text] [Related]  

  • 15. PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
    Zhang RN; Shen F; Pan Q; Cao HX; Chen GY; Fan JG
    World J Gastroenterol; 2021 Jul; 27(25):3863-3876. PubMed ID: 34321850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
    Tasneem AA; Luck NH; Majid Z
    Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.